Structural Insights into Substrate Binding and Antibiotic Inhibition of Enterobacterial Penicillin-Binding Protein 6
- PMID: 35888109
- PMCID: PMC9320039
- DOI: 10.3390/life12071022
Structural Insights into Substrate Binding and Antibiotic Inhibition of Enterobacterial Penicillin-Binding Protein 6
Abstract
Shigella sonnei remains the second most common cause of shigellosis in young children and is now increasingly dominant across developing countries. The global emergence of drug resistance has become a main burden in the treatment of S. sonnei infections and β-lactam antibiotics, such as pivmecillinam and ceftriaxone, are recommended to be used as second-line treatment. They work by inhibiting the biosynthesis of the peptidoglycan layer of bacterial cell walls, in which the final transpeptidation step is facilitated by penicillin-binding proteins (PBPs). In this study, using protein homology modelling, we modelled the structure of PBP6 from S. sonnei and comprehensively examined the molecular interactions between PBP6 and its pentapeptide substrate and two antibiotic inhibitors. The docked complex of S. sonnei PBP6 with pentapeptides showed that the substrate bound to the active site groove of the DD-carboxypeptidase domain, via hydrogen bonding interactions with the residues S79, V80, Q101, G144, D146 and R240, in close proximity to the catalytic nucleophile S36 for the nucleophilic attack. Two residues, R240 and T208, were found to be important in ligand recognition and binding, where they formed strong hydrogen bonds with the substrate and β-lactams, respectively. Our results provide valuable information on the molecular interactions essential for ligand recognition and catalysis by PBP6. Understanding these interactions will be helpful in the development of effective drugs to treat S. sonnei infections.
Keywords: Shigella sonnei; antibiotic inhibition; homology modelling; molecular docking; penicillin-binding protein 6; pentapeptide binding.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





References
-
- Gu B., Cao Y., Pan S., Zhuang L., Yu R., Peng Z., Qian H., Wei Y., Zhao L., Liu G., et al. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009. Int. J. Antimicrob. Agents. 2012;40:9–17. doi: 10.1016/j.ijantimicag.2012.02.005. - DOI - PubMed
-
- Pai H., Choi E.H., Lee H.J., Hong J.Y., Jacoby G.A. Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J. Clin. Microbiol. 2001;39:3747–3749. doi: 10.1128/JCM.39.10.3747-3749.2001. - DOI - PMC - PubMed
-
- WHO . Guidelines for the Control of Shigellosis, Including Epidemics due to Shigella Dysenteriae Type 1. World Health Organization; Geneva, Switzerland: 2005. [(accessed on 15 June 2022)]. Available online: https://apps.who.int/iris/handle/10665/43252.
Grants and funding
LinkOut - more resources
Full Text Sources